Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Stergios J MoschosShahneen SandhuKarl D LewisRyan J SullivanIgor PuzanovDouglas B JohnsonHaby A HenaryHansen WongVijay V UpretiGeorgina V LongKeith T Flaherty

Published in: Investigational new drugs (2022)

The maximum tolerated dose of AMG 232 for both arms was 120 mg. AMG 232 plus T±D exhibited a favorable PK profile. Although objective responses occurred in both arms, adding AMG 232 to T±D did not confer additional clinical benefit.

Keyphrases

wild type
signaling pathway
oxidative stress
open label
cancer therapy
randomized controlled trial
clinical trial
pi k akt
cell proliferation
placebo controlled